venglustat
Small moleculeexperimental
Clinical trial activity
12 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
6
Phase 3
6
Phase 4
0
Earliest trial started Aug 16, 2018 (NCT06421714)
Timeline
Indications
Mechanism of action
- Ceramide glucosyltransferaseINHIBITOR
UGCG inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)c1csc(-c2ccc(F)cc2)n1- Mol. weight
- 389.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297611 ↗
Also known as
- venglustat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05718258 | Phase 1 | Jan 18, 2023 | Sanofi |
| NCT05280548 | Phase 3 | May 3, 2022 | Genzyme, Sanofi |
| NCT05222906 | Phase 3 | Apr 18, 2022 | Genzyme, Sanofi |
| NCT05206773 | Phase 3 | Mar 11, 2022 | Sanofi |
| NCT04705051 | Phase 3 | Feb 9, 2021 | Sanofi |
| NCT06418607 | Phase 1 | Jun 23, 2020 | Sanofi |
| NCT06418620 | Phase 1 | Jun 18, 2020 | Sanofi |
| NCT05238714 | Phase 1 | May 26, 2020 | Genzyme, Sanofi |
| NCT04221451 | Phase 3 | Mar 25, 2020 | Genzyme, Sanofi |
| NCT03687554 | Phase 1 | Sep 25, 2018 | Sanofi |
| NCT03523728 | Phase 3 | Aug 21, 2018 | Genzyme, Sanofi |
| NCT06421714 | Phase 1 | Aug 16, 2018 | Genzyme |
Showing 12 of 12 trials
Page 1 / 1